Missing content? – Request curation!
Request curation for specific Genes, Variants, or PubMed publications.
Have questions, comments, or suggestions? - Let us know!
Email us at : ckbsupport@genomenon.com
| Therapy Name | 225Ac-PSMA-R2 |
| Synonyms | |
| Therapy Description |
225Ac-PSMA-R2 is a radioconjugate comprising the PSMA-targeting ligand PSMA-R2 linked to the radionuclide actinium-225, which delivers alpha radiation to PSMA-expressing tumor cells, potentially inducing cell killing (NCI Drug Dictionary). |
| Drug Name | Trade Name | Synonyms | Drug Classes | Drug Description |
|---|---|---|---|---|
| 225Ac-PSMA-R2 | 225AcPSMA-R2|Ac225-PSMA-R2|[225Ac]Ac-PSMA-R2 | PSMA Antibody 22 | 225Ac-PSMA-R2 is a radioconjugate comprising the PSMA-targeting ligand PSMA-R2 linked to the radionuclide actinium-225, which delivers alpha radiation to PSMA-expressing tumor cells, potentially inducing cell killing (NCI Drug Dictionary). |
| Molecular Profile | Indication/Tumor Type | Response Type | Therapy Name | Approval Status | Evidence Type | Efficacy Evidence | References |
|---|
| Clinical Trial | Phase | Therapies | Title | Recruitment Status | Covered Countries | Other Countries |
|---|---|---|---|---|---|---|
| NCT05983198 | Phase Ib/II | 225Ac-PSMA-R2 | Phase I/II Study of [225Ac]Ac-PSMA-R2 in PSMA-positive Prostate Cancer, With/Without Prior 177Lu-PSMA RLT (SatisfACtion) | Recruiting | USA | FRA | CAN | AUS | 0 |